Barinthus Biotherapeutics PLC
BRNS1.300USD
-0.100-7.14%
Market hours （ET）Quotes delayed by 15 min
52.44MMarket Cap
LossP/E TTM
More Details of Barinthus Biotherapeutics PLC Company
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. It is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease.
Company Info
Ticker SymbolBRNS
Company nameBarinthus Biotherapeutics PLC
IPO dateApr 30, 2021
CEOMr. William J. (Bill) Enright
Number of employees105
Security typeDepository Receipt
Fiscal year-endApr 30
AddressUnit 6-10, Zeus Building, Rutherford Avenue
CityDIDCOT
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited Kingdom
Postal codeOX11 0DF
Phone441865818808
Websitehttps://www.barinthusbio.com/
Ticker SymbolBRNS
IPO dateApr 30, 2021
CEOMr. William J. (Bill) Enright
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Ms. Karen T. Dawes
Ms. Karen T. Dawes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 4
Updated: Fri, Jul 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Oxford Science Enterprises PLC
21.81%
M&G Investment Management Ltd.
12.88%
Cawood (Frank Wayne)
8.39%
Alphabet, Inc.
3.75%
HSG Holding Ltd.
3.52%
Other
49.64%
Shareholders
Shareholders
Proportion
Oxford Science Enterprises PLC
21.81%
M&G Investment Management Ltd.
12.88%
Cawood (Frank Wayne)
8.39%
Alphabet, Inc.
3.75%
HSG Holding Ltd.
3.52%
Other
49.64%
Shareholder Types
Shareholders
Proportion
Venture Capital
25.56%
Investment Advisor
18.09%
Individual Investor
13.54%
Corporation
0.92%
Investment Advisor/Hedge Fund
0.53%
Endowment Fund
0.30%
Hedge Fund
0.15%
Research Firm
0.04%
Other
40.87%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
40
23.85M
59.13%
+716.00K
2025Q1
41
23.85M
60.03%
+745.95K
2024Q4
40
24.08M
59.87%
+1.54M
2024Q3
37
20.03M
50.21%
-349.60K
2024Q2
38
20.26M
51.12%
-213.80K
2024Q1
38
20.04M
50.62%
-468.31K
2023Q4
42
19.97M
51.73%
-616.84K
2023Q3
45
19.96M
51.78%
-695.67K
2023Q2
52
20.10M
52.29%
-1.03M
2023Q1
51
20.44M
53.30%
-692.87K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Oxford Science Enterprises PLC
8.80M
21.81%
--
--
Apr 14, 2025
M&G Investment Management Ltd.
5.20M
12.88%
--
--
Mar 31, 2025
Cawood (Frank Wayne)
3.38M
8.39%
+1.04M
+44.47%
Dec 31, 2024
Alphabet, Inc.
1.51M
3.75%
--
--
Mar 31, 2025
HSG Holding Ltd.
1.42M
3.52%
--
--
Mar 31, 2025
Enright (William)
1.24M
3.08%
--
--
Apr 14, 2025
DC Funds, LP
642.20K
1.59%
--
--
Mar 31, 2025
Lynn (Geoffrey)
638.44K
1.58%
+638.44K
--
Dec 17, 2024
Gilead Sciences Inc
369.86K
0.92%
-250.50K
-40.38%
Mar 31, 2025
Johns Hopkins University
122.24K
0.3%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
